# US 2017/0253588 A1 · Salt of naphthyridine carboxylic acid derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253588 A1
- Document ID: US20170253588A1
- Status: Published application
- Kind: A1
- Application number: 15/411,030
- Filed: 2017-01-20
- Published: 2017-09-07
- Earliest claimed: 1997-03-21
- Assignees: LG Life Sciences Ltd.
- Applicants: LG Life Sciences, Ltd.
- Inventors: Ae Ri Kim; Jin Hwa Lee; Ki Sook Park; Jong Ryoo Choi; Tae Hee Lee; Jay Hyok Chang; Do Hyun Nam; Hoon Choi
- Web page: https://patentgrep.com/patent/US20170253588A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61P 11/16: Central respiratory analeptics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 31/04: Antibacterial agents
- C07C 309/04: containing only one sulfo group
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.

## Claims

### Claim 1

7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate.

### Claim 2

7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate.nH2O, wherein n is in the range of from 1 to 4.

### Claim 3 (depends on 2)

A compound according to claim 2 wherein n is 1.5.

### Claim 4 (depends on 2)

A compound according to claim 2 having peaks at 2θ=8.0, 12.2 and 14.7° in its X-ray diffraction pattern.

### Claim 5 (depends on 2)

A compound according to claim 2 having an X-ray diffraction pattern substantially as shown in FIG. 7.

### Claim 6 (depends on 2)

A compound according to claim 2 where n is 3.

### Claim 7 (depends on 2)

A compound according to claim 2 having peaks at 2θ=7.7, and 11.8° in its X-ray diffraction pattern.

### Claim 8 (depends on 2)

A compound according to claim 2 having an X-ray diffraction pattern substantially as shown in FIG. 6.

### Claim 9 (depends on 2)

A compound according to claim 2 which has a moisture content of from 4 to 6%.

### Claim 10 (depends on 2)

A compound according to claim 2 which has a moisture content of from 9 to 11%.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, together with a pharmaceutically acceptable carrier or excipient.

### Claim 12 (depends on 1)

A compound according to claim 1, for use as a pharmaceutical.

### Claim 13 (depends on 1)

A method of treating bacterial infections in humans and animals which comprises administering a therapeutically effective amount of a compound according to claim 1.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A process for the preparation of a compound according to claim 1, which comprises reacting 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid with methanesulfonic acid and crystallizing the resulting compound from solution, and where desired or necessary, adjusting the hydration of the compound.

### Claim 16 (depends on 2)

A process for the preparation of a compound according to claim 2, comprising exposing 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate anhydrate or a solvate thereof to a relative humidity of at least 75%.

### Claim 17 (depends on 16)

A process according to claim 16, wherein the solvate is a solvate with one or more organic solvents selected from C1-C4 haloalkanes and C1-C8 alcohols.

### Claim 18

A solvate of 7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate with one or more organic solvents.
